Prestige Consumer Healthcare Inc. (PBH) Stock Price & How to Invest

Prestige Consumer Healthcare Inc. owns over-the-counter healthcare brands rather than inventing them. The portfolio spans Monistat and Summer's Eve in women's health, BC and Goody's pain powders, Clear Eyes and TheraTears eye care, Dramamine, Fleet, Chloraseptic, Luden's, DenTek, Compound W, Nix, Debrox and Boudreaux's Butt Paste, plus Gaviscon in Canada and Hydralyte and the newly acquired Dermal Therapy line in Australia. Most manufacturing is outsourced, so spending goes to advertising and shelf presence instead of factories. Two segments carry the results: North American OTC Healthcare produced about $226 million of the June 2026 quarter's roughly $266 million, and International OTC Healthcare the remaining $40 million. Concentration is real on both ends, with the top five brands at about 39 percent of gross revenue, Walmart at roughly 19 percent and Amazon at roughly 16 percent. The fiscal year ends in March, so the quarter reported on August 6, 2026 was the first of fiscal 2027.

The financial shape is a steady cash generator carrying debt raised to buy brands. Fiscal 2026 revenue fell to about $1,088.7 million from about $1,137.8 million as Clear Eyes supply problems bit, and the shares dropped sharply on the May 13, 2026 report. June brought the largest deal in years: about $1,045 million in cash for Breathe Right and related brands, funded with a new seven-year term loan, followed by LaCorium Health in Australia on a further $95 million draw. Net debt moved from roughly $0.93 billion at the March year end to about $2.0 billion by June 30, 2026, close to the company's own equity market value. Management raised fiscal 2027 guidance to roughly $1,290 million to $1,315 million of revenue and $270 million or more of adjusted free cash flow, and paused open-market buybacks to repay borrowings instead.

Clear Eyes supply remains unreliable, and the Pillar5 remediation intended to fix it is a live drag on gross margin rather than a completed project. Net debt of roughly $2.0 billion now sits close to the entire equity market value, and first-quarter interest expense of about $13.9 million reflected only a few weeks of the new term loan, so the run-rate cost of that debt is materially higher from here. Customer concentration cuts both ways: Walmart was roughly 19 percent of gross revenue last quarter and Amazon roughly 16 percent, and Amazon also sells competing house-brand versions of several categories Prestige plays in. Private label and store brands, supplied at scale by Perrigo and sold as Equate, Up and Up and Amazon Basic Care, price against Prestige's brands directly whenever household budgets tighten. Several plaintiff law firms announced investigations after the May 13, 2026 fiscal 2026 results, though as of the Form 10-Q filed August 6, 2026 no securities class action with a case number had been filed and the company disclosed only routine legal matters.

5 analysts publish price targets on PBH, averaging $67.80 against a $50.57 price as of August 2026, or +34.1%. The published targets run from $55.00 to $75.00, a narrow spread, and the ratings split 5 buy, 2 hold, 0 sell. Over the last six months there have been 0 raises and 3 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full PBH forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Prestige Consumer Healthcare Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. The biggest acquisition in years just closed. Prestige paid about $1,045 million in cash for Breathe Right and an associated group of brands on June 12, 2026, then drew a further $95 million to buy LaCorium Health, whose Dermal Therapy line leads therapeutic skin care in Australia. The most optimistic published target, $75.00, assumes this works close to its best case.

The case against. Clear Eyes supply remains unreliable, and the Pillar5 remediation intended to fix it is a live drag on gross margin rather than a completed project. The most pessimistic target, $55.00, is roughly what PBH is worth if this bites instead.

Read the full bull and bear case on PBH, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Prestige Consumer Healthcare Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$1.10B, through the quarter ended June 30, 2026
• Latest quarter (Q1 FY2027): ~$265.7M revenue, up ~6.5%, with ~3.2% organic growth
• Diluted EPS (Q1 FY2027): ~$0.61 GAAP and ~$0.98 adjusted, versus ~$0.95 adjusted a year earlier
• Fiscal 2027 company outlook: ~$1,290M to ~$1,315M revenue, ~$4.55 to ~$4.65 adjusted EPS, ~$270M or more adjusted free cash flow
• Market cap: ~$2.4B on ~47.4M shares outstanding
• Valuation and balance sheet: ~2.2x TTM sales and ~11x the fiscal 2027 adjusted EPS midpoint, against ~$2.0B of net debt

Fiscal 2026, which ended March 31, 2026, brought revenue of about $1,088.7 million against about $1,137.8 million the year before, so the trailing figure reflects a down year already in the base. The trailing multiple looks undemanding next to consumer staples generally, and the reason is visible on the balance sheet: enterprise value including roughly $2.0 billion of net debt is a very different number from the roughly $2.4 billion equity value. Guidance for fiscal 2027 is not comparable to fiscal 2026 without adjustment, because it now folds in two acquisitions that closed in June and July 2026.

Other names that sit close to PBH: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get PBH exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so PBH sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where PBH fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

A cash-generative portfolio of household over-the-counter brands whose fiscal 2027 question is whether the Breathe Right and LaCorium acquisitions grow fast enough to pay down the debt that bought them.

Whether PBH is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is PBH a buy or a sell?, and where the stock could go from here in the PBH stock forecast.

For income investors, whether PBH pays a dividend and how the payout looks is covered in does PBH pay a dividend? And to weigh PBH against a peer, read the full side-by-side comparisons: PBH vs KVUE and PBH vs HLN.